America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

burger_pills.jpg

Part II.  What Do We Get for All That Money?  A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic;  Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;

Continue reading →

Safety Issues: FDA Scientists Collide with FDA Managers

Since 1995 FDA scientists have been at odds against FDA managers who routinely override sientists’ safety concerns to approve dubious prescription drugs.

Continue reading →

FDA Scientists Collide with FDA Managers Re: Safety Issues

Since 1995 FDA scientists have been at odds against FDA managers who routinely override sientists’ safety concerns to approve dubious prescription drugs. Continue reading →

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known. Continue reading →

Congress & the White House must remedy a prescription for danger – LA Times / CBS News

Congress & the White House must remedy a prescription for danger – LA Times / CBS News Thu, 1 Apr 2004 For those who missed the CBS evening News broadcast (Tues March 30) about FDA’s suppression of evidence, a video of that . . . Continue reading →

Forbes: Face of The Year: David Graham

Forbes: Face of The Year: David Graham Mon, 13 Dec 2004   Forbes magazine has named Dr. David Graham the Face of the Year’ for his “steadfast advocacy of drug safety and his willingness to blow the whistle on his bosses.” Dr. . . . Continue reading →

FDA’s Double Standard Re: Advisory Committee Membership

FDA’s Double Standard Re: Advisory Committee Membership Mon, 15 Nov 2004 FDA’s inexplicable actions–the latest being the removal of Dr. Curt Furberg from an FDA advisory committee for alleged "intellectual conflict of interest" – demonstrate hypocracy and intellectual dishonesty. Dr. Furberg independently . . . Continue reading →

FDA’s Lethal Weakness Requires More than Committees

FDA’s Lethal Weakness Requires More than Committees Sun, 7 Nov 2004 Bloomberg News reports that New York State Attorney General Eliot Spitzer requested information from Pfizer about the promotion of some of its drugs for unapproved uses – the recalled diabetes drug, . . . Continue reading →